Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis Distinguishing Between Particle Concentration, Type, and Content

被引:145
作者
Marston, Nicholas A. [1 ]
Giugliano, Robert P. [1 ]
Melloni, Giorgio E. M. [1 ]
Park, Jeong-Gun [1 ]
Morrill, Valerie [2 ]
Blazing, Michael A. [3 ]
Ference, Brian [4 ]
Stein, Evan [5 ]
Stroes, Erik S. [6 ]
Braunwald, Eugene [1 ]
Ellinor, Patrick T. [2 ,7 ,8 ]
Lubitz, Steven A. [2 ,7 ,8 ]
Ruff, Christian T. [1 ]
Sabatine, Marc S. [1 ]
机构
[1] Brigham & Womens Hosp, Harvard Med Sch, Thrombolysis Myocardial Infarct TIMI Study Grp, Boston, MA 02115 USA
[2] Broad Inst MIT & Harvard, Cardiovasc Dis Initiat, Cambridge, MA 02142 USA
[3] Duke Univ, Dept Med, Durham, NC USA
[4] Univ Cambridge, Cambridge, England
[5] Metab & Atherosclerosis Res Ctr, Cincinnati, OH USA
[6] Univ Med Ctr Amsterdam, Amsterdam, Netherlands
[7] Harvard Med Sch, Cardiovasc Res Ctr, Massachusetts Gen Hosp, Boston, MA 02115 USA
[8] Harvard Med Sch, Demoulas Ctr Cardiac Arrythmias, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
NON-HDL CHOLESTEROL; LDL CHOLESTEROL; CARDIOVASCULAR OUTCOMES; DISCORDANCE; RATIONALE; DISEASE; EVENTS; DESIGN;
D O I
10.1001/jamacardio.2021.5083
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Lipid management typically focuses on levels of low-density lipoprotein cholesterol (LDL-C) and, to a lesser extent, triglycerides (TG). However, animal models and genetic studies suggest that the atherogenic particle subpopulations (LDL and very-low-density lipoprotein [VLDL]) are both important and that the number of particles is more predictive of cardiac events than their lipid content. OBJECTIVE To determine whether common measures of cholesterol concentration, TG concentration, or their ratio are associated with cardiovascular risk beyond the number of apolipoprotein B (apoB)-containing lipoproteins. DESIGN, SETTING, AND PARTICIPANTS This prospective cohort analysis included individuals from the population-based UK Biobank and from 2 large international clinical trials, FOURIER and IMPROVE-IT. The median (IQR) follow-up was 11.1 (10.4-11.8) years in UK Biobank and 2.5 (2.0-4.7) years in the clinical trials. Two populations were studied in this analysis: 389 529 individuals in the primary prevention group who were not taking lipid-lowering therapy and 40 430 patients with established atherosclerosis who were receiving statin treatment. EXPOSURES ApoB, non-high-density lipoprotein cholesterol (HDL-C), LDL-C, and TG. MAIN OUTCOME AND MEASURES The primary study outcome was incident myocardial infarction (MI). RESULTS Of the 389 529 individuals in the primary prevention group, 224 097 (58%) were female, and the median (IQR) age was 56.0 (49.5-62.5) years. Of the 40 430 patients with established atherosclerosis, 9647 (24%) were female, and the median (IQR) age was 63 (56.2-69.0) years. In the primary prevention cohort, apoB, non-HDL-C, and TG each individually were associated with incident MI. However, when assessed together, only apoB was associated (adjusted hazard ratio [aHR] per 1 SD, 1.27; 95% CI, 1.15-1.40; P <.001). Similarly, only apoB was associated with MI in the secondary prevention cohort. Adjusting for apoB, there was no association between the ratio of TG to LDL-C (a surrogate for the ratio of TG-rich lipoproteins to LDL) and risk of MI, implying that for a given concentration of apoB-containing lipoproteins, the relative proportions of particle subpopulations may no longer be a predictor of risk. CONCLUSIONS AND RELEVANCE In this cohort study, risk of MI was best captured by the number of apoB-containing lipoproteins, independent from lipid content (cholesterol or TG) or type of lipoprotein (LDL or TG-rich). This suggests that apoB may be the primary driver of atherosclerosis and that lowering the concentration of all apoB-containing lipoproteins should be the focus of therapeutic strategies.
引用
收藏
页码:250 / 256
页数:7
相关论文
共 22 条
  • [1] VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins
    Balling, Mie
    Afzal, Shoaib
    Varbo, Anette
    Langsted, Anne
    Smith, George Davey
    Nordestgaard, Borge G.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (23) : 2725 - 2735
  • [2] Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis
    Boekholdt, S. Matthijs
    Arsenault, Benoit J.
    Mora, Samia
    Pedersen, Terje R.
    LaRosa, John C.
    Nestel, Paul J.
    Simes, R. John
    Durrington, Paul
    Hitman, Graham A.
    Welch, K. M. A.
    DeMicco, David A.
    Zwinderman, Aeilko H.
    Clearfield, Michael B.
    Downs, John R.
    Tonkin, Andrew M.
    Colhoun, Helen M.
    Gotto, Antonio M., Jr.
    Ridker, Paul M.
    Kastelein, John J. P.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (12): : 1302 - 1309
  • [3] The UK Biobank resource with deep phenotyping and genomic data
    Bycroft, Clare
    Freeman, Colin
    Petkova, Desislava
    Band, Gavin
    Elliott, Lloyd T.
    Sharp, Kevin
    Motyer, Allan
    Vukcevic, Damjan
    Delaneau, Olivier
    O'Connell, Jared
    Cortes, Adrian
    Welsh, Samantha
    Young, Alan
    Effingham, Mark
    McVean, Gil
    Leslie, Stephen
    Allen, Naomi
    Donnelly, Peter
    Marchini, Jonathan
    [J]. NATURE, 2018, 562 (7726) : 203 - +
  • [4] Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
    Cannon, Christopher P.
    Giugliano, Robert P.
    Blazing, Michael A.
    Harrington, Robert A.
    Peterson, John L.
    Sisk, Christine McCrary
    Strony, John
    Musliner, Thomas A.
    McCabe, Carolyn H.
    Veltri, Enrico
    Braunwald, Eugene
    Califf, Robert M.
    [J]. AMERICAN HEART JOURNAL, 2008, 156 (05) : 826 - 832
  • [5] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    Cannon, Christopher P.
    Blazing, Michael A.
    Giugliano, Robert P.
    McCagg, Amy
    White, Jennifer A.
    Theroux, Pierre
    Darius, Harald
    Lewis, Basil S.
    Ophuis, Ton Oude
    Jukema, J. Wouter
    De Ferrari, Gaetano M.
    Ruzyllo, Witold
    De Lucca, Paul
    Im, KyungAh
    Bohula, Erin A.
    Reist, Craig
    Wiviott, Stephen D.
    Tershakovec, Andrew M.
    Musliner, Thomas A.
    Braunwald, Eugene
    Califf, Robert M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) : 2387 - 2397
  • [6] Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease
    Castaner, Olga
    Pinto, Xavier
    Subirana, Isaac
    Amor, Antonio J.
    Ros, Emilio
    Hernaez, Alvaro
    Angel Martinez-Gonzalez, Miguel
    Corella, Dolores
    Salas-Salvado, Jordi
    Estruch, Ramon
    Lapetra, Jose
    Gomez-Gracia, Enrique
    Alonso-Gomez, Angel M.
    Fiol, Miquel
    Serra-Majem, Lluis
    Corbella, Emili
    Benaiges, David
    Sorli, Jose V.
    Ruiz-Canela, Miguel
    Babio, Nancy
    Sierra, Lucas Tojal
    Ortega, Emilio
    Fito, Montserrat
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (23) : 2712 - 2724
  • [7] Association of Apolipoprotein B and Nuclear Magnetic Resonance Spectroscopy-Derived LDL Particle Number with Outcomes in 25 Clinical Studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices
    Cole, Thomas G.
    Contois, John H.
    Csako, Gyorgy
    McConnell, Joseph P.
    Remaley, Alan T.
    Devaraj, Sridevi
    Hoefner, Daniel M.
    Mallory, Tonya
    Sethi, Amar A.
    Warnick, G. Russell
    [J]. CLINICAL CHEMISTRY, 2013, 59 (05) : 752 - 770
  • [8] The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine
    Elliott, Paul
    Peakman, Tim C.
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2008, 37 (02) : 234 - 244
  • [9] Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease
    Ference, Brian A.
    Kastelein, John J. P.
    Ray, Kausik K.
    Ginsberg, Henry N.
    Chapman, John
    Packard, Chris J.
    Laufs, Ulrich
    Oliver-Williams, Clare
    Wood, Angela M.
    Butterworth, Adam S.
    Di Angelantonio, Emanuele
    Danesh, John
    Nicholls, Stephen J.
    Bhatt, Deepak L.
    Sabatine, Marc S.
    Catapano, Alberico L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (04): : 364 - 373
  • [10] Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
    Johannesen, Camilla Ditlev Lindhardt
    Mortensen, Martin Bodtker
    Langsted, Anne
    Nordestgaard, Borge Gronne
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (11) : 1439 - 1450